Similarly, Shamili et al. isolated EVs derived from murine BM-MSCs overexpressing TRAIL and showed that the administration of the encapsulated form of TRAIL was better at reducing tumor size in vivo than the free drug (Shamili et al., 2018). The gene discussed is TNFSF10; the disease is neoplasm.